Associated Genetic Biomarkers
NCI Definition: A ganglioneuroblastoma characterized by the presence of neuroblastic cells in a Schwannian stroma, and the formation of hemorrhagic neuroblastic nodules. 
There are 2 clinical trials for ganglioneuroblastoma, nodular, of which 2 are open and 0 are completed or closed. Of the trials that contain ganglioneuroblastoma, nodular as an inclusion criterion, 2 are phase 2 (2 open).
MYCN is the most frequent gene inclusion criterion for ganglioneuroblastoma, nodular clinical trials .
Dinutuximab, isotretinoin, and sargramostim are the most common interventions in ganglioneuroblastoma, nodular clinical trials.
Significant Genes in Ganglioneuroblastoma, Nodular
MYCN is an inclusion eligibility criterion in 1 clinical trial for ganglioneuroblastoma, nodular, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and ganglioneuroblastoma, nodular as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.